Epstein–barr virus, immunodeficiency, and b cell lymphoproliferation

Transplantation

Volumn 39, Issue 5, 1985, Pages 461-472

  Hanto, Douglas W ^a   Frizzera, Glauco ^a   Gajl Peczalska, Kazimiera J ^a   Simmons, Richard L ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELL NUCLEUS ANTIGEN; EARLY ANTIGEN; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; VIRUS ANTIBODY; VIRUS CAPSID ANTIGEN;

B LYMPHOCYTE; BLOOD AND HEMOPOIETIC SYSTEM; BONE MARROW TRANSPLANTATION; EPSTEIN BARR VIRUS; HUMAN; IMMUNE DEFICIENCY; INFECTIOUS MONONUCLEOSIS; LYMPHATIC SYSTEM; LYMPHOCYTE PROLIFERATION; LYMPHOPROLIFERATIVE DISEASE; PRIORITY JOURNAL; REVIEW; SURVEY; VIRUS REPLICATION; X CHROMOSOME LINKED DISORDER;

ANIMAL; ATAXIA TELANGIECTASIA; B-LYMPHOCYTES; BONE MARROW TRANSPLANTATION; CLONE CELLS; HERPESVIRUS 4, HUMAN; HUMAN; IMMUNITY; KIDNEY TRANSPLANTATION; LYMPHOMA; LYMPHOPROLIFERATIVE DISORDERS; SUPPORT, U.S. GOV'T, P.H.S.; THYMUS GLAND; TRANSPLANTATION IMMUNOLOGY; VIRUS REPLICATION;

EID: 0022263464     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007890-198505000-00001     Document Type: Article

References (166)

1. Sixbey -IW, Nedrud J l, Raab-Traub N, Hanes RA, Pagano JS. Epstein-Barr virus replication in oropharyngeal epithelial cells. N Engl J Med 1984; 310; 1225.
2. londal M, Klein O. Surface markers on human B and T lympho cytes: 11. Presence of Epstein-Barr virus receptors on B lymphocytes..1 Exp Med 1973; 138: 1365.
3. Rosen A, Gergely P,.fondai M, Klein G, Britton S. Polyclonal Ig production after Epstein-Barr virus infection of human lymphocytes in vitro. Nature 1977; 267: 52.
4. Kirchner H, Tosato G, Blaese RM, et al. Polyclonal immunoglob ulin secretion by human B lymphocytes exposed to Epstein- Barr virus in vitro. J Immunol 1979; 122: 1310.
5. Robinson IE, Brown N, Andiman W, et al. Diffuse polyclonal B-cell lymphoma during primary infection with Epstein-Barr virus. N Engl.J Med 1980; 302: 1293.
6. Henle G, Henle W. The virus as the etiologic agent of infectious mononucleosis. In: Epstein MA, Achong BG, eds. The Epstein- Barr virus. New York: Springer-Verlag, 1979: 297.
7. Klein E, Masucci MG. Cell-mediated immunity against Epstein-Barr virus infected B lymphocytes. Springer Semin Immuno- pathol 1982; 5: 63.
8. Pearson GR, Orr TW. Antibody-dependent lymphocyte cytotox icity against cells experiencing Epstein-Barr virus antigens. J Natl Cancer Inst 1976; 56: 485.
9. Blazar BA, Patarroyo M, Klein E, Klein G. Increased sensitivity of human lymphoid lines to natural killer cells after induction of the Epstein-Barr viral cycle by superinfection or sodium butyrate. J Exp Med 1980; 151: 614.
10. Penman HG. Fatal infectious mononucleosis: a critical review. J Clin Pathol 1971; 23: 765.
11. Bar RS, DeLor CJ, Clauren KP, Hurtubise P, Henle W, Hervetson JF. Fatal infectious mononucleosis in a family. N Engl J Med 1974; 290: 363.
12. Hanto DW, Gajl-Peczalska KJ, Frizzera G, et al. Epstein-Barr virus (EBV) induced polyclonal and monoclonal B-cell lympho- proliferative diseases occurring after renal transplantation. Ann Surg 1983; 198: 356.
13. Bieber CP, Heberling RL, Jamieson SW, et al. Lymphoma in cardiac transplant recipients associated with cyclosporin A, prednisone and anti-thymocyte globulin (ATG). In: Purtilo DT, ed. Immune deficiency and cancer. New York: Plenum, 1984: 309.
14. Starzl TE, Nalesnik MA, Porter KA, et al. Reversibility of lym phomas and lymphoproliferative lesions developing under cy- closporin-steroid therapy. Lancet 1984: 1: 583.
15. Schubach WH, Hackman R, Neiman PE, Miller G, Thomas ED. A monoclonal immunoblastic sarcoma in donor cells bearing Epstein-Barr virus genomes following allogeneic marrow grafting for acute lymphoblastic leukemia. Blood 1982; 60: 180.
16. Reece ER, Gartner JG, Seemayer TA, Joncas JH, Pagano JS. Epstein-Barr virus in a malignant lymphoproliferative disorder of B-cells occurring after thymic epithelial transplantation for combined immunodeficiency. Cancer Res 1981; 41: 4243.
17. Sullivan JL. Epstein-Barr virus and the X-linked lymphoprolif erative syndrome. Adv Pediatr 1984; 30: 365.
18. Saemundsen AK, Berkel Al, Henle W, et al. Epstein-Barr virus DNA in a patient with ataxia-telangiectasia. Br Med J 1981; 282: 425.
19. Frizzera G, Hanto DW, Gajl-Peczalska KJ, et al. Polymorphic diffuse B-cell hyperplasias and lymphomas in renal transplant recipients. Cancer Res 1981; 41: 4262.
20. Hanto DW, Frizzera G, Gajl-Peczalska KJ, et al. Epstein-Barr virus-induced B-cell lymphoma after renal transplantation. N Engl J Med 1982; 306: 913.
21. Cleary ML, Warnke R, Sklar J. Monoclonality of lymphoprolif erative lesions in cardiac-transplant recipients. N Engl J Med 1984; 310: 477.
22. Cleary ML, Sklar J. Lymphoproliferative disorders in cardiac transplant recipients are multiclonal lymphomas. Lancet 1984; 2: 489.
23. Epstein MA, Achong BG. Introduction: discovery and general biology of the virus. In: Epstein MA, Achong BG, eds. The Epstein-Barr virus. New York.Springer Verlag, 1979: 1.
24. Miller G. Biology of the Epstein-Barr virus. In: Klein G, ed. Viral oncology. New York:Raven, 1980: 713.
25. Epstein MA, Achong BG, eds. The Epstein-Barr virus. New York:Springer Verlag, 1979.
26. Bird AG, Britton S. The relationship between Epstein-Barr virus and lymphoma. Semin Hematol 1982; 19: 285.
27. Sugden B. Epstein-Barr virus: a human pathogen inducing lym-phoproliferation in vivo and in vitro. Rev Infect Dis 1982; 4: 1048.
28. Katsuki T, Hinuma Y, Yamamato N, Abo T, Kumagai K. Identification of the target cells in human B lymphocytes for transformation of Epstein-Barr virus. Virology 1977; 83: 1287.
29. Greaves MF, Brown G, Rickinson AB. Epstein-Barr virus binding sites on lymphocyte subpopulations and the origin of lymphoblasts in cultured lymphoid cell lines and in the blood of patients with infectious mononucleosis. Clin Immunol Immunopathol 1975; 3: 514.
30. Yefenov E, Klein G, Jondal J., et al. Surface markers on human B and T lymphocytes IX: two color immunofluorescence studies on the association between EBV receptors and complement receptors on the surface of lymphoid cell lines. Int J Cancer 1976; 17: 693.
31. Yefenov E, Klein G. Membrane receptor stripping confirms the association between EBV receptors and complement receptors on the surface of human B lymphoma lines. Int J Cancer 1977; 20: 347.
32. Jondal M, Klein G, Oldstone MBA, Bokish V, Yefenof E. Surface markers on human B and T lymphocytes: VIII. Association between complement and Epstein-Barr virus receptors on human lymphoid cells. Scand J Immunol 1976; 5: 401.
33. Bird AG, Britton S. A live human B-cell activator operating in isolation of other cellular influences. Scand J Immunol 1979; 9: 507.
34. Sugden B, Mark W. Clonal transformation of adult human leu kocytes by Epstein-Barr virus. J Virol 1977; 23: 503.
35. Klein G, Svedmyr E, Jondal M, Persson PO. EBV-determined nuclear antigen (EBNA) positive cells in the peripheral blood of infectious mononucleosis patients. Int J Cancer 1976; 17: 21.
36. Klein G. Lymphoma development in mice and humans: diversity of initiation is followed by convergent cytogenetic evolution. Proc Natl Acad Sci USA 1979; 76: 2442.
37. Nilsson K, Giovanella BC, Stehlin JS, Klein G. Tumorigenicity of human hematopoietic cell lines in athymic nude mice. Int J Cancer 1977; 19: 337.
38. Chang RS, Lewis JP, Abildgaard CF. Prevalence of oropharyngeal excreters of leukocyte-transforming agents among a human population. N Engl J Med 1973; 289: 1325.
39. Chang RS, Lewis JP, Reynolds RD, Sullivan MJ, Neuman J. Oropharyngeal excretion of Epstein-Barr virus by patients with lymphoproliferative disorders and by recipients of renal homografts. Ann Int Med 1978; 88: 34.
40. Strauch B, Siegel N, Andrews LL, Miller G. Oropharyngeal excretion of Epstein-Barr virus by renal transplant recipients and other patients treated with immunosuppressive drugs. Lancet 1974; 1: 234.
41. Lemon SM, Hutt LM, Shaw JE, Li J-LH, Pagano JS. Replication of EBV in epithelial cells during infectious mononucleosis. Nature 1977; 268: 268.
42. Morgan DG, Miller G, Niederman JC, Smith HW, Dowaliby JM. Site of Epstein-Barr virus replication in the oropharynx. Lancet 1979; 2: 1154.
43. Wolf H, Bayliss GJ, Wilmes E. Biologic properties of Epstein-Barr virus. In: Grundman E, Krueger GRF, Ablaski DV, eds. Nasopharyngeal carcinoma. Cancer Campaign vol. 15. Stutt- gard:Fischer Verlag, 1981: 101.
44. Glaser R, Lang CM, Lee KJ, Schuller DE, Jacobs D, McQuattie C. Attempt to infect nonmalignant nasopharyngeal epithelial cells from humans and squirrel monkeys with Epstein-Barr virus. J Natl Cancer Inst 1980; 64: 1085.
45. Shapiro IM, Volsky DJ. Infection of normal human epithelial cells by Epstein-Barr Virus. Science 1983; 219: 1225.
46. Klein G. The relationship of the virus to nasopharyngeal carcinoma. In: Epstein MA, Achong BG, eds. The Epstein-Barr virus. New York:Springer-Verlag, 1979: 339.
47. Stoerker J, Parris D, Yajima Y, Glasez R. Pleiotropic expression of Epstein-Barr virus DNA in human epithelial cells. Proc Natl Acad Sci USA 1981; 78: 5852.
48. Miller G, Gordon E, Heston L, Robinson J, Smith D. Epstein-Barr viral DNA: infectivity for human placental cells. Science 1981; 212: 452.
49. Graessman A, Wolf H, Bornkamm GW. Expression of Epstein-Barr virus genes in different cell types after microinjection of viral DNA. Proc Natl Acad Sci USA 1980; 77: 433.
50. Volsky DJ, Shapiro IM, Klein G. Transfer of Epstein-Barr virus (EBV) receptors to receptor negative cells permits virus penetration and antigen expression. Proc Natl Acad Sci USA 1980; 77: 5453.
51. Sixbey JW, Vesterinen EH, Nedrud JG, Raab-Traub N, Walton LA, Pagano JS. Replication of Epstein-Barr virus in human epithelial cells infected in vitro. Nature 1983; 306: 480.
52. Miller G. Epstein-Barr virus-immortalization and replication. N Engl J Med 1984; 310: 1255.
53. Henle W, Henle G. Epstein-Barr virus: specific serology in im-munologically compromised individuals. Cancer Res 1982; 41: 4222.
54. Henle W, Henle G. Seroepidemiology of the virus. In: Epstein MA, Achong BG, eds. The Epstein-Barr virus. New York:Springer-Verlag, 1979: 61.
55. Sakamoto K, Freed HJ, Purtilo DT. Antibody responses to Epstein-Barr virus in families with the X-linked lymphoprolifer- ative syndrome. J Immunol 1980; 12.5: 921.
56. Joncas J, LaPointe N, Gervais F, Leyritz M. Unusual prevalence of Epstein-Barr virus early antigen (EBV-EA) antibody in ataxia telangiectasia..J Immunol 1977; 119: 1857.
57. Berkel AI, Henle W, Henle G, Klein G, Ersoy F, Sanal O. Epstein-Barr virus-related antibody patterns in ataxia-telangiectasia. Clin Exp Immunol 1979; 35: 196.
58. Lange B, Henle W, Meyers JD, et al. Epstein-Barr virus-related serology in marrow transplant recipients. Int J Cancer 1980; 26: 151.
59. Svedmyr E, Jondal M. Cytotoxic effector cells specific for B-cell lines transformed by Epstein-Barr virus are present in patients with infectious mononucleosis. Proc Natl Acad Sci USA 1975; 72: 1622.
60. Royston J, Sullivan JL, Periman PO, Perkins E. Cell mediated immunity to Epstein-Barr virus-transformed lymphoblastoid cells in acute infectious mononucleosis. N Engl J Med 1975; 293: 1159.
61. Lipinski M, Fridman WH, Tursz T, Vincent C, Pious D, Fellows M. Absence of allogeneic restrictions in human T-cell-mediated cytotoxicity to Epstein-Barr virus-infected target cells: demonstration of an HLA-linked control at the effector level. J Exp Med 1979; 150: 1310.
62. Seeley J, Svedmyr E, Weiland O, et al. Epstein-Barr virus selective T-cells in infectious mononucleosis are not restricted to HLA- A and B antigens. J Immunol 1981; 127: 293.
63. Jondal M, Svedmyr E, Klein E. Epstein-Barr virus (EBV) specific T and K cell cytotoxicity in vitro. In: Clemmeson J, Yohn DS, eds. Comparative leukemia research. Bibl Haematologica 1975; 43: 265.
64. Thorley-Lawson DA, Chess L, Strominger JL. Suppression of invitro Epstein-Barr virus infection: a new role for adult human T lymphocytes. J Exp Med 1977; 146: 495.
65. Moss DJ, Rickinson AB, Pope JH. Long-term T-cell-mediated immunity to Epstein-Barr virus in man: I. Complete regression of virus-induced transformation in cultures of seropositive- donor leukocytes. Int J Cancer 1978; 22: 662.
66. Moss DJ, Rickinson AB, Pope JH. Long-term T-cell mediated immunity to Epstein-Barr virus in man: III. Activation of cytotoxic T cells in virus-infected leukocyte cultures. Int J Cancer 1979; 23: 618.
67. Rickinson AB, Crawford DH, Epstein MA. Inhibition of the invitro outgrowth of Epstein-Barr virus-transformed lymphocytes by thymus-dependent lymphocytes from infectious mononucleosis patients. Clin Exp Immunol 1977; 28: 72.
68. Rickinson AB, Moss DJ, Wallace LE, et al. Long-term T-cell-mediated immunity to Epstein-Barr virus. Cancer Res 1981; 41: 4216.
69. Rickinson AB, Moss DJ, Pope JP. Long-term T-cell-mediated immunity to Epstein-Barr virus in man: II. Components necessary for regression in virus infected leukocyte cultures. Int J Cancer 1979; 23: 610.
70. Sugamura K, Hinuma Y. In vitro induction of cytotoxic T lymphocytes specific for Epstein-Barr virus-transformed cells: kinetics of autologous restimulation. J Immunol 1980; 124: 1045.
71. Tanaka Y, Sugamura K, Hinuma Y. Heterogeneity of allogeneic restriction of human cytotoxic T cell clones specific for Epstein- Barr virus. J Immunol 1982; 128: 1241.
72. Fukukawa T, Hirano T, Sakaguchi N, et al. In vitro induction of HLA-restricted cytotoxic T lymphocytes against autologous Epstein-Barr virus transformed B lymphoblastoid cell line. J Immunol 1981; 126: 1697.
73. Tsoukas CD, Fox RI, Solvin SF, et al. T lymphocyte-mediated cytotoxicity against autologous EBV-genome-bearing cells. J Immunol 1981; 126: 1742.
74. Moss DJ, Wallace LE, Rickinson AB, Epstein MA. Cytotoxic T cell recognition of Epstein-Barr virus-infected B cells: I. Specificity and HLA restriction of effector cells reactivated in vitro. Eur J Immunol 1981; 11:686.
75. Wallace LE, Moss DJ, Rickinson AB, McMichael AJ, Epstein MA. Cytotoxic T cell recognition of Epstein-Barr virus-infected B cells: II. Blocking studies with monoclonal antibodies to HLA determinants. Eur J Immunol 1981; 11: 694.
76. Wallace LE, Rowe M, Gaston JSH, Rickinson AB, Epstein MA. Cytotoxic T-cell recognition of Epstein-Barr virus-infected B cells: III. Establishment of HLA-restricted cytotoxic T cell lines using interleukin 2. Eur J Immunol 1982; 12: 1012.
77. Wallace LE, Rickinson AB, Rowe M, Epstein MA. Epstein-Barrvirus-specific cytotoxic T-cell clones restricted through a single HLA antigen. Nature 1982; 297: 413.
78. Gaston JSH, Rickinson AB, Epstein MA. Cross-reactivity of self-HLA-restricted Epstein-Barr virus-specific cytotoxic T lymphocytes for allo-HLA determinants. J Exp Med 1983; 158: 1804.
79. Bird AG, McLachlan SM. Cyclosporin A and Epstein-Barr virus. Lancet 1980; 2: 418.
80. Bird AG, McLachlan SM, Britton S. Cyclosporin A promotes spontaneous outgrowth in vitro of Epstein-Barr virus-induced B-cell lines. Nature 1981; 289: 300.
81. Crawford DH, Edwards JMB, Sweny P, Hoffbrand AV, Janossy G. Studies on long-term T-cell-mediated immunity to Epstein- Barr virus in immunosuppressed renal allograft recipients. Int J Cancer 1981; 28: 705.
82. Crawford DH, Edwards JMB, Sweny P, Janossy G, Hoffbrand AV. Long-term T-cell-mediated immunity to Epstein-Barr virus in renal-allograft recipients receiving cyclosporin A. Lancet 1981; 1: 10.
83. Crawford DH, Edwards JMB. Immunity to Epstein-Barr virus in cyclosporin A-treated renal allograft recipients. Lancet 1982; 1: 1469.
84. Gaston JSH, Rickinson AB, Epstein MA. Epstein-Barr-virus-specific T-cell memory in renal-allograft recipients under longterm immunosuppression. Lancet 1982; 1: 923.
85. Blazar BA, Fitzgerald J, Sutton L, Strome M. Increased sensitivity to natural killing in Raji cells is due to effector recognition of molecules appearing on target cell membranes following EBV cycle induction. Clin Exp Immunol 1983; 54: 31.
86. Pearson GR, Qualtiere LF, Klein G, Norin T, Bal IS. Epstein-Barr virus-specific antibody-dependent cellular cytotoxicity in patients with Burkitt's lymphoma. Int J Cancer 1979; 24: 402.
87. Mathew GD, Qualtiere LJ, Neel HB III, Pearson GR. IgA Anti body, antibody-dependent cellular cytotoxicity and prognosis in patients with nasopharyngeal carcinoma. Int J Cancer 1981; 27: 175.
88. Lipinski M, Tursz T, Kreis H, Finale Y, Amiel JL. Dissociation of natural killer cell activity and antibody-dependent cell-mediated cytotoxicity in kidney allograft recipients receiving high- dose immunosuppressive therapy. Transplantation 1980; 29: 214.
89. Szigeti R, Luka J, Klein G. Leukocyte migration inhibition studie swith Epstein-Barr virus (EBV) determined nuclear antigen (EBNA) in relation to the EBV-carrier status of the donor. Cell Immunol 1981; 58: 269.
90. Szigeti R, Volsky DJ, Luka J, Klein G. Membranes of EBV-carrying virus nonproducer cells inhibit leukocyte migration of EBV-seropositive hut not seronegative donors. Immunol 1981; 126: 1676.
91. Szigeti R, Luka J, Sternas L, Klein G. Migration inhibition caused by EBV-specific 48K subcomponent of EBNA and the associated 53K cellular protein. Int J Cancer 1982; 29: 413.
92. Szigeti R, Masucci G, Ehlin-Henriksson B, et al. EBNA-specific LIF production of human lymphocyte subsets. Cell Immunol 1984; 83: 136.
93. Penn I. The price of immunotherapy. Curr Probl Surg 1981; 18: 681.
94. Hanto DW, Simmons RL. Association of cancer with renal transplantation. In: Rieselbach RE, Garnick MB, eds. Cancer and the kidney. Philadelphia: Lea and Febiger, 1982; 869.
95. Hoover R, Fraumeni -IF,.Jr. Risk of cancer in renal-transplant recipients. Lancet 1973; 2: 55.
96. Penn I. Lymphomas complicating organ transplantation. Transplant Proc 1983; 15: 2790.
97. Klein G, Klein E. Immune surveillance against virus-induced tumors and nonrejectabilitv of spontaneous tumors: contrasting consequences of host versus tumor evolution. Proc Natl Acad Sci USA 1977; 74: 2121.
98. Louie S, Schwartz RS. Immunodeficiency and the pathogenesis of lymphoma and leukemia. Semin Hematol 1978; 15: 117.
99. Gleichmann E, Gleichman H, Schwartz RS, Weinblatt A, Armstrong MYK. Immunologic induction of malignant lymphoma: identification of donor and host tumors in the graft-versus-host model..J Natl Cancer Inst 1975; 54: 107.
100. Matas AJ, Simmons RL, Najarian JS. Chronic antigenic stimulation, herpesvirus infection, and cancer in transplant recipients. Lancet 1975; 1; 1277.
101. Spencer ES, Andersen HK. Antibodies to the Epstein-Barr virusin kidney transplant recipients. Acta Med Scand 1972; 191: 107.
102. Marker SC, Ascher NL, Kalis JM, Simmons RL, Najarian JS, Balfour HH Jr. Epstein-Barr virus antibody responses and clinical illness in renal transplant recipients. Surgery 1979; 85: 433.
103. Grose C, Henle W, Horwitz MS. Primary Epstein-Barr virusinfection in a renal transplant recipient. South Med J 1977; 70: 1276.
104. Hertel BF, Rosai J, Dehner P, Simmons RL. Lymphoproliferative disorders in organ transplant recipients. Lab Invest 1977; 36: 340.
105. Lukes RJ, Collins RD. Immunologic characterization of human malignant lymphomas. Cancer 1974; 34(suppl): 1488.
106. Nagington J, Gray J. Cyclosporin A immunosuppression, Epstein-Barr antibody, and lymphoma. Lancet 1980; 1: 536.
107. Crawford DH, Thomas JA, Janossy G, et al. Epstein-Barr virus nuclear antigen positive lymphoma after cyclosporin A treatment in patient with renal allograft. Lancet 1980; 1: 1355.
108. Hanto DW, Gajl-Peczalska KJ, Purtilo D, Klein G, Simmons RL, Najarian JS. The Epstein-Barr virus (EBV) in the pathogenesis of post-transplant lymphoma. Transplant Proc 1981; 13: 756.
109. Hanto DW, Frizzera G, Purtilo DT, et al. Clinical spectrum of lymphoproliferative disorders in renal transplant recipients and evidence for the role of Epstein-Barr virus. Cancer Res 1981; 41: 4261.
110. Hanto DW, Sakamoto K, Purtilo DT, Simmons RL, Najarian JS. The Epstein-Barr virus in the pathogenesis of posttransplant lymphoproliferative disorders. Surgery 1981; 90: 204.
111. Hanto DW, Simmons RL. Lymphoproliferative diseases in im-munosuppressed patients. In: Morris PJ, Tilney NL, eds. Progress in transplantation. Edinburgh:Churchill Livingstone, 1984: 186.
112. Tubman DE, Frick MP, Hanto DW. Lymphoma after organ transplantation: radiologic manifestations in the central nervous system, thorax, and abdomen. Radiology 1983; 149: 625.
113. Frick MP, Salomonowitz E, Hanto DW, Gedgaudas-McCIees K. CT of abdominal lymphoma after renal transplantation. AJR 1984; 142: 97.
114. Cheeseman SH, Henle W, Rubin RH, Tolkoff-Rubin NE, et al. Epstein-Barr virus infection in renal transplant recipients: effects of antithymocyte globulin and interferon. Ann Intern Med 1980: 93: 39.
115. Caine RY, Rolles K, White DJG, et al. Cyclosporin A initially as the only immunosuppressant in 34 recipients of cadaveric organs: 32 kidneys, 2 pancreases, and 2 livers. Lancet 1979; 2; 1033.
116. Schneck SA, Penn I. De-novo brain tumors in renal-transplant recipients. Lancet 1971; 1: 983.
117. Weintraub J, Warnke RA. Lymphoma in cardiac allotransplant recipients. Transplantation 1982; 33: 347.
118. Zulman J, Jaffe R, Talal N. Evidence that the malignant lym phoma of Sjogren's syndrome is a monoclonal B-cell neoplasm. N Engl J Med 1978; 299: 1215.
119. Zulman J, Jaffe R, Talal N.Editorial. Lymphoma in organ transplant recipients. Lancet 1984; 1: 601.
120. Malcolm S, Barton P, Murphy C, Ferguson-Smith MA, Bentley L, Rabbitts TN. Localization of human immunoglobulin k light chain variable region genes to the short arm of chromosome 2 by in situ hybridization. Proc Natl Acad Sci USA 1982; 79: 4957.
121. Kirsch IR, Morton CC, Nakahara K, Leder P. Human immune globulin heavy chain genes map to a region of translocations in malignant B lymphocytes. Science 1982; 216: 301.
122. Erickson J, Martinis J, Croce CM. Assignment of the genes for human X immunoglobulin chains to chromosome 22. Nature 1981; 294: 173.
123. McBride OW, Hieter PA, Hollis GF, Swan D, Otez MC, Leder P. Chromosomal location of human kappa and lambda immunoglobulin light chain constant region genes. J Exp Med 1982; 155: 1480.
124. Lenoir GM, Prud'homme JL, Bernheim A, Berger R. Correlation between immunoglobulin light chain expression and variant translocation in Burkitt’s lymphoma. Nature 1982; 298: 474.
125. Hecht F, Kaise-McCaw B. Immunoglobulin expression in Burk-itt's lymphoma and leukemia. N Engl J Med 1982; 307: 1583.
126. Saemundsen AK, Purtilo DT, Sakamoto K, et al. Documentation of Epstein-Barr virus infection in immunodeficient patients with life-threatening lymphoproliferative diseases by Epstein- Barr virus complementary RNA/DNA and viral DNA/DNA hybridization. Cancer Res 1981; 41: 4237.
127. Saemundsen AK, Klein G, Cleary M, Warnke R. EBV-carrying lymphoma in cardiac transplant recipients. Lancet 1982; 2: 158.
128. Colby BM, Shaw JE, Elion GB, Pagano JS. Effect of acyclovir 9-(2-hydroxyethoxymethyl) guanine] on Epstein-Barr virus DNA replication. J Virol 1980; 34: 560.
129. Datta AK, Colby BM, Shaw JE, Pagano JS. Acyclovir inhibition of Epstein-Barr virus replication. Proc Natl Acad Sci USA 1980; 77: 5163.
130. Hanto DW, Frizzera G, Gajl-Peczalska KJ, et al. Acyclovir therapy of Epstein-Barr virus (EBV)-induced posttransplant lymphoproliferative diseases. Transplant Proc 1985; 17: 89.
131. Isaacson P, Wright DH. Extranodal malignant lymphoma arising from mucosa associated lymphoid tissue. Cancer 1984; 53: 2515.
132. Hochberg FH, Miller G, Schooley RT, Hirsch MS, Feorino P, Henle W. Central-nervous-system lymphoma related to Ep- stein-Barr virus. N Engl J Med 1983; 309: 745.
133. Santos GW, Kaizer H. Bone marrow transplantation in acute leukemia. Semin Hematol 1982; 19: 227.
134. Sullivan JL, Wallen WC, Johnson FL. Epstein-Barr virus infection following bone-marrow transplantation Int J Cancer 1978; 22: 132.
135. Purtilo DT, Paquin LA, Sakamoto K, et al. Persistent transfusion-associated infectious mononucleosis with transient acquired immunodeficiency. Am J Med 1980; 68: 437.
136. Gossett TC, Gale RP, Fleischman H, Austin GE, Sparkes RS, Taylor CR. Immunoblastic sarcoma in donor cells after bone- marrow transplantation. N Engl J Med 1979; 300: 904.
137. Purtilo DT. Pathogenesis and phenotypes of an X-linked recessive lymphoproliferative syndrome. Lancet 1976; 2: 882.
138. Purtilo DT, DeFlorio D, Jr., Hutt LM, et al. Variable phenotypic expression of an X-linked recessive lymphoproliferative syndrome. N Engl J Med 1977; 297: 1077.
139. Purtilo DT, Yang JPS, Allegra S, et al. Hematopathology and pathogenesis of the X-linked recessive lymphoproliferative syndrome. Am J Med 1977; 62: 225.
140. Purtilo DT, Paquin L, DeFlorio D, Virzi F, Sakhuja R. Immuno-diagnosis and immunopathogenesis of the X-linked recessive lymphoproliferative syndrome. Semin Hematol 1979; 16: 309.
141. Purtilo DT. Epstein-Barr virus-induced oncogenesis in immune-deficient individuals. Lancet 1980; 1: 300.
142. Purtilo DT, Sakamoto K, Barnabei V, et al. Epstein-Barr virus-induced diseases in boys with the X-linked lymphoproliferative syndrome (XLP). Am J Med 1982; 73: 49.
143. Purtilo DT, Sakamoto K, Saemundsen AK, et al. Documentation of Epstein-Barr virus infection in immunodeficient patients with life-threatening lymphoproliferative diseases by clincal virological, and immunopathological studies. Cancer Res 1981; 41: 4226.
144. Harada S, Sakamoto K, Seeley JK, et al. Immune deficiency in the X-linked lymphoproliferative syndrome: I. Epstein-Barr virus-specific defects. J Immunol 1982; 129: 2532.
145. Sullivan JL, Byron K, Brewster F, Purtilo DT. Deficient natural killer cell activity in the X-linked lymphoproliferative syndrome. Science 1980; 210: 543.
146. Harada S, Bechtold T, Seeley JK, Purtilo DT. Cell-mediated immunity to Epstein-Barr virus (EBV) and natural killer (NK)- cell activity in the X-linked lymphoproliferative syndrome. Int J Cancer 1982; 30: 739.
147. Seeley JK, Sakamoto K, Ip SH, Hansen P, Purtilo DT. Abnormal lymphocytes subsets in X-linked lymphoproliferative syndrome. J Immunol 1981; 127: 2618.
148. Lindsten T, Seeley JK, Ballow M, et al. Immune deficiency in the X-linked lymphoproliferative syndrome: II. Immunoregulatory T cell defects. J Immunol 1982; 129: 2536.
149. Filipovich AH, Zerbe D, Spector BD. Kersey JH. Lymphomas in persons with naturally occurring immunodeficiency disorders. In: Magrath IT, O’Conor GT, Ramot B, eds. Pathogenesis of leukemias and lymphomas: environmental influences. New York: Raven, 1984: 225.
150. Saemundsen AK, Berkel Al, Henle W, et al. Epstein-Barr virus-carrying lymphoma in a patient with ataxia-telangiectasia. Br Med J 1981; 282: 425.
151. Borzy MS, Hong R, Horowitz SD, et al. Fatal lymphoma after transplantation of cultured thymus in children with combined immunodeficiency disease. N Engl J Med 1979; 301: 565.
152. Shope T, Dechairo D, Miller G. Malignant lymphoma in cottontop marmosets after inoculation with Epstein-Barr virus. Proc Natl Acad Sci USA 1973; 70: 2487.
153. Werner J, Wolf H, Apodaca J, zur Hausen H. Lymphoproliferative disease in a cotton-top marmoset after inoculation with infectious mononucleosis-derived Epstein-Barr virus. Int J Cancer 1975; 15: 1000.
154. Frank A, Andiman WA, Miller G. Epstein-Barr virus and non human primates: natural and experimental infection. Adv Cancer Res 1976; 23: 171.
155. Miller G, Shope T, Coope D, et al. Lymphoma in cotton-top marmosets after inoculation with Epstein-Barr virus: tumor incidence, histologic spectrum, antibody responses, demonstration of viral DNA, and characterization of viruses. J Exp Med 1977; 145: 948.
156. Johnson DR, Wolfe LG, Levan G, Klein G, Ernberg I, Aman P. Epstein-Barr virus (EBV)-induced lymphoproliferative disease in cotton-topped marmosets. Int J Cancer 1983; 31: 91.
157. Miller G. Experimental carcinogenicity by the virus in vivo. In: Epstein MA, Achong BG, eds. The Epstein-Barr virus. New York:Springer-Verlag, 1979: 351.
158. Epstein MA, Hunt RD, Rahin H. Pilot experiments with EB virus in owl monkeys (Aotus Trivirgatus): I. Reticuloproliferative disease in an inoculated animal. Int J Cancer 1973; 12: 309.
159. Leibold W, Huldt G, Flanagan TG, et al. Tumorigenicity of Epstein-Barr virus (EBV)-transformed lymphoid line cells in autologous squirrel monkeys. Int J Cancer 1976; 17: 533.
160. Falk L, Deinhardt F, Wolfe L, Johnson D, Hilgers J, de The' G. Epstein-Barr virus. Experimental infection of Callithrix Jaccus marmosets. Int J Cancer 1976; 13: 785.
161. Sundar SK, Levine PH, Ahlashi DV, et al. Epstein-Barr virus-induced malignant lymphoma in a white-lipped marmoset. Int J Cancer 1981; 27: 107.
162. Miller G, Lipman M. Release of infectious Epstein-Barr virus by transformed marmoset leukocytes. Proc Natl Acad Sci USA 1973; 70: 190.
163. Nickerson D, Gengozian N. Functional capabilities of marmoset T and B lymphocytes in primary in vitro antibody formation. Cell Immunol 1981; 57: 408.
164. Abb J, Abb H, Deinhardt F. Cell-mediated immune response of marmosets to herpesvirus-associated antigen in vitro. Cancer Immunol Immunother 1980; 9: 219.
165. Rabin H, Neubauer R, Hopkins R, Levy B. Characterization of lymphoid cell lines established from multiple Epstein-Barr virus (EBV)-induced lymphomas in a cotton-topped marmoset. Int J Cancer 1977; 20: 44.
166. Epstein MA, Achong BG. Recent progress in Epstein-Barr virus research. Annu Rev Microbiol 1977; 31: 421.